We provide valuable medicines to rare disease patients
The lack of satisfactory treatments for rare diseases results in high unmet medical needs for patients and increases the need for orphan drugs and niche specialty pharmaceuticals.
Read more about our mission.
We care about rare disease patients
Our vision is to be a premier international pharmaceutical company focused on providing valuable orphan drugs and niche specialty products and services to patients with high unmet medical needs.
Read more about our vision.
We are advancing our clinical development pipe-line
Several late -stage rare disease clinical development protein pharmaceutical programs and an advancing preclinical development pipe-line may provide exciting additional patient and commercial value.
Read more about our R&D activities.
We will expand our portfolio of niche specialty products
Currently our portfolio contains some 60 products. Our focus areas are: hemophilia, inflammation/autoimmune diseases, cancer supportive care and inherited metabolic disorders.
Read more about our business development.
Sobi's first quarter results 2012
Sobi’s interim report for January - March 2012 was published on 26 April 2012
A telephone conference was held the same day, hosted by CEO Geoffrey McDonough, COO Alan Raffensperger and CFO Lars Sandström .
Swedish Orphan Biovitrum (Sobi)
Sobi is a leading integrated biopharmaceutical company
Dedicated to bringing innovative therapies and services to improve the health of rare disease patients and their families.
Protein Therapeutic Development
Our late stage clinical project portfolio
We currently have projects within hemophilia / hematology, autoimmune diseases / inflammation and inherited metabolic disorders in our development pipeline.